Objectives: The aim of this study was to examine the effectof smoking on the efficacy of raloxifene treatment inpostmenopausal osteoporosis.Materials and methods: In this cross-sectional study,raloxifene HCl (60 mg/day) and 600 mg ionized calcium+ 400 IU vitamin D/day treatment were given to 63 cases(nonsmoker group n= 39, smoker group n= 24), who werein the postmenopausal period and detected as having osteoporosis.At the end of the first year of the treatment, thebone mineral densities (BMDs; g/cm2) were measured atfour regions, namely the femur neck, femur trochanter, totalhip, and lumbar vertebrae between L1-4, and T-scoreswere determined. The changes in BMDs were comparedbetween the two groups.Results: Before starting the treatment, the mean ages(55.8 ± 3.3 vs. 53.0 ± 1.3 years), menopausal ages (49.3± 2.9 vs. 48.1 ± 2.1 years), postmenopausal periods (5.0± 1.3 vs. 7.0 ± 1.4 years), body mass indexes, and estradiollevels were found to be significantly not differentbetween the two groups (p > 0.05). At the beginning oftreatment, the BMD values were not different for all measuredregions in both groups (p > 0.05). At the end of thefirst year of the treatment, statistically significant improvementsin BMD values and T-scores were detected for allmeasured regions in the nonsmoker group (p < 0.05).However, there were no significant differences in theBMD values from the initial values in the smoker groupafter treatment (p > 0.05).Conclusions: The treatment efficacy of raloxifene in improvingBMD values in postmenopausal osteoporosis isnegatively influenced by smoking. J Clin Exp Invest 2012;3(4): 457-462Key words: Raloxifene, postmenopausal osteoporosis,smokin
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.